Evolving Topics Among Oncologists Treating Gynecologic Cancers
In Partnership With
John P. Diaz, MD, explains the importance of the topics to be discusses at the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.
John P. Diaz, MD, the chief of Gynecologic Oncology, lead physician for Clinical Trials in Gynecologic Oncology at MCI, and chief of the Center of Excellence in Minimally Invasive Gynecologic Surgery, Baptist Health South Florida, explains the importance of the topics to be discusses at the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.
The treatment landscape for gynecologic malignancies is evolving, according to Diaz. The Miami Cancer Institute Women’s Cancer Symposium brings together oncologists from across the country to discuss the recent changes and the future of treatment.
Transcript:
0:08 | As each meeting has continued to evolve, and we've had such advances in gynecologic oncology that it's very timely. We talked a little bit about the role of immunotherapy in the treatment of endometrial cancers. We've also recently had our first 2 new drug classes, approved for the treatment of gynecologic malignancies. The first was an antibody-drug conjugate that was approved for the treatment of recurrent and metastatic cervical cancer. And Dr. Lesley Randall is going to be talking to us about the role and the updates in the treatment of cervical cancer.
0:38 | More recently, we just had an antibody-drug conjugate that was approved for the treatment of women with recurrent platinum-resistant ovarian cancer. And so, Kathleen Moore, MD, MS from University of Oklahoma is going to come talk about that. In addition, we've invited Robert Coleman, MD, FACOG, FACS to come talk about maintenance therapy for ovarian cancer. Ovarian cancer has really changed the way that we treat it particularly the upfront setting and maintenance therapy has become standard of care. And we have so many options. The question is what's the best option for patients? Do we use bevacizumab [Avastin]? Do we use PARP inhibitors? Do we use PARP inhibitors with VEGF inhibitors? And so, Coleman is going to shed some light on those topics. So, it's a really exciting time in gynecologic oncology, and we thought it was very opportunistic for us to have this meeting with these great speakers from across the United States.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
